Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy

Strong Results But Merck & Co’s Keytruda Also Competing

Mar 28 2023

GSK needs its own PD1/L1 therapy 'backbone' on which to build future cancer therapy combinations. • Source: GSK